Navigation Links
Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
Date:9/16/2009

SAN DIEGO, Sept. 16 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the UBS Global Life Sciences Conference in New York.

The live presentation takes place Wednesday, September 23, 2009 at 1:00 p.m. Eastern Time (ET)/10:00 a.m. Pacific Time (PT). The presentation will be simultaneously webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600. Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

About Neurocrine

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurocrine Biosciences Secures Committed Equity Financing Facility
2. Neurocrine Biosciences Reports Second Quarter 2009 Results
3. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results
5. Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference
6. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
7. Neurocrine Biosciences Reports First Quarter 2009 Results
8. Neurocrine Announces Work Force Restructuring
9. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
10. Neurocrine Biosciences to Present at the Cowen and Company 29th Annual Health Care Conference
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, ... announced its U.S. joint venture with G-treeBNT (ReGenTree ... phase 3 clinical trial for the orphan disorder, ... trial for dry eye syndrome (DES) in the ... eye drops, RGN-259/GBT201, this year.  Each of these ...
(Date:4/16/2015)... PHOENIX, AZ (PRWEB) April 16, 2015 ... and makes it easier for research institutions to learn ... collect clinical data. , The timing is ideal since ... on Tuesday. Research Kit is an open-source framework for ... 9. It provides a way for researchers to collect ...
(Date:4/16/2015)... DIEGO , April 16, 2015 Avelas ... dedicated to improving cancer surgeries, announced today that it ... fluorescent cancer illuminator, AVB-620, in women with primary, non-recurrent ... the company also welcomed the addition of Steven ... The open label, dose escalation study will ...
(Date:4/16/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company ... new orphan drug indications, today announced that the ... a clinical trial site for the ongoing, multicenter Phase ... multiforme (GBM), the most common and deadly form of ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5
... Colo., Sept. 4 InVitria,( http://www.invitria.com ... animal free,products that enhance productivity, safety ... the biopharmaceutical, cell culture, life science ... of Cambridge Healthtech,Institute,s 4th Annual "Optimizing ...
... Institutes and The University of North Carolina-Chapel Hill ... in Drug Safety Sciences, RESEARCH TRIANGLE PARK, N.C., ... the University of North Carolina at,Chapel Hill announced they ... will be led by Dr. Paul Watkins, one of ...
... CARLOS, Calif., Sept. 4 SleepQuest has partnered,with ... breathing, to conduct clinical trials of a new ... Apnea from,wherever they are sleeping. The technology is ... used to improve the quality of care for ...
Cached Biology Technology:InVitria Sponsors Cambridge Healthtech's Optimizing Cell Culture Development Conference 2New Hamner-UNC Center for Drug Safety Sciences 2New Hamner-UNC Center for Drug Safety Sciences 3Latest Sleep Disorder Technology Tested With SleepQuest 2
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
(Date:4/6/2015)... Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA ... NXT-ID introduces a new revolutionary method ... surrounds the use of miniature antenna modules for ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... issue of Proceedings of the National Academy ... mathematical models to analyze huge amounts of data ... in different ocean habitats and metabolic activity in ... in unprecedented detail how environment influences molecular changes ...
... State University process to pretreat corn-crop waste before ... to be added, cutting the cost of making ... expansion) pretreatment process, developed by Bruce Dale, University ... uses ammonia to make the breakdown of cellulose ...
... According to Professor Demain, the petroleum-based economy in the ... lifecycle. Global oil reserves and new petroleum discoveries will ... It is therefore essential to anticipate and avoid any ... new bioenergy alternatives for the marketplace. In the ...
Cached Biology News:Mixing genomics and geography yields insights into life and environment 2Process can cut the cost of making cellulosic biofuels 2
EML1 (K-16)...
Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
Bovine Aortic Smooth Muscle Cells (BAOSMC) (>500,000 cells)...
... allows the Thermo-Fast® 96 ... PCR plates to be ... PRISM® 3700 capillary sequencer. ... information on the software ...
Biology Products: